Merck (MRK) Other Working Capital Changes (2009 - 2026)
Merck (MRK) reported Other Working Capital Changes of $1.6 billion for Q1 2026, down 56.55% year-over-year from $3.7 billion in Q1 2025, and up 219.48% quarter-over-quarter from -$1.4 billion in Q4 2025.
Merck (MRK) Other Working Capital Changes (2009 - 2026) Analysis & Trends
Merck (MRK) has 18 years of Other Working Capital Changes data on file, last reported at $1.6 billion in Q1 2026.
- Other Working Capital Changes for Q1 2026 came in at $1.6 billion, down 56.55% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.2 billion (down 30.81% YoY), and the FY2025 annual result was $3.3 billion, up 133.55% from the prior year.
- Other Working Capital Changes improved to $1.6 billion in Q1 2026 per MRK's latest filing, from -$1.4 billion in the prior quarter.
- Over five years, Other Working Capital Changes peaked at $3.7 billion in Q1 2025 and troughed at -$2.6 billion in Q3 2024.
- A 5-year average of $595.5 million and a median of $1.0 billion in 2024 frame the typical range for Other Working Capital Changes.
- The sharpest annual moves came in 2024 and 2025: Other Working Capital Changes slumped 1031.43% in 2024, then jumped 123.22% in 2025.
- A 5-year view of Other Working Capital Changes shows it stood at -$962.0 million in 2022, then soared by 96.36% to -$35.0 million in 2023, then tumbled by 1031.43% to -$396.0 million in 2024, then sank by 240.91% to -$1.4 billion in 2025, then surged by 219.48% to $1.6 billion in 2026.
- Business Quant data shows MRK's Other Working Capital Changes at $1.6 billion in Q1 2026, -$1.4 billion in Q4 2025, and -$1.3 billion in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn |
| 10 | Novartis Ag | 108.28 Bn | 107.60 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.61 Bn |
| Mar 31, 2026 | 1.61 Bn |
| Dec 31, 2025 | -1.35 Bn |
| Dec 31, 2025 | -1.35 Bn |
| Sep 30, 2025 | -1.31 Bn |
| Sep 30, 2025 | -1.31 Bn |
| Jun 30, 2025 | 2.26 Bn |
| Jun 30, 2025 | 2.26 Bn |
| Mar 31, 2025 | 3.71 Bn |
| Mar 31, 2025 | 3.71 Bn |
| Dec 31, 2024 | -396.00 Mn |
| Dec 31, 2024 | -396.00 Mn |
| Sep 30, 2024 | -2.58 Bn |
| Sep 30, 2024 | -2.58 Bn |
| Jun 30, 2024 | 1.01 Bn |
| Jun 30, 2024 | 1.01 Bn |
| Mar 31, 2024 | 3.38 Bn |
| Mar 31, 2024 | 3.38 Bn |
| Dec 31, 2023 | -35.00 Mn |
| Dec 31, 2023 | -35.00 Mn |